Background Prostate cancer (PC) is the most common cancer in Western countries. More
than one third of PC patients develop metastatic disease, and the 5-year expected survival …

Background Treatment of metastatic prostate cancer is associated with high personal and
economic burden. Recently, new treatment options for castration-resistant prostate cancer …

BACKGROUND: In the past decade, many oncologic drugs have been approved that extend
life and/or improve patients' quality of life. However, new cancer drugs are often associated …

Purpose Prostate cancer is the second leading cause of cancer death in men in the US.
Since 2015, landmark studies have demonstrated improved survival outcomes with the use …

Aims: Among patients diagnosed with prostate cancer, 10–20% will develop castration-
resistant prostate cancer (CRPC) within 5 years; for 70%, CRPC will metastasize, mostly to …

Objectives To evaluate the efficacy and safety of abiraterone acetate‐prednisone versus
placebo‐prednisone in Asian metastatic castration‐resistant prostate cancer patients who …

Background Inhibition of the adenosine 2A receptor (A2AR) diminishes the
immunosuppressive effects of adenosine and may complement immune-targeting drugs …

Of patients diagnosed with prostate cancer, 0% to 20% experience disease progression to
metastatic castration-resistant prostate cancer (mCRPC). Recently, 4 novel therapies have …

Background Several randomized control trials (RCTs) have showed that adding either
abiraterone acetate (AA) or docetaxel (D) to androgen-deprivation therapy (ADT) improves …

The objective is to examine the cost–utility of sipuleucel-T immunotherapy in asymptomatic
or minimally symptomatic castration-resistant prostate cancer patients. The addition of …